Galderma Reports First Half 2026 Financial Results

Galderma Group AG announced its financial results for the first half of 2026.

Flemming Ørnskov, M.D., MPH, Chief Executive Officer of Galderma, said:

“Galderma delivered a strong first half of 2026, with broad-based growth across geographies and product categories, reflecting the strength of our integrated dermatology strategy. Our upcoming inclusion in the Swiss Market Index, Switzerland’s leading blue-chip equity index, effective September 21, is an important milestone in our journey as a listed company and further recognition of Galderma’s progress. Building on this momentum, we are raising our full-year net sales growth guidance as we continue to advance our dermatology powerhouse ambition.”

For the first half of 2026, Galderma achieved net sales of $3,134 million, surpassing $3 billion for the first time in the first six months of a year. Year-on-year net sales growth was 24.6% at constant currency, predominantly driven by volume and complemented by favorable mix. 

Net sales growth remained broad-based, with double-digit growth in most of Galderma’s top 10 markets and across all product categories. Galderma continued to outperform the market in each of its product categories.

For Galderma, 2026 remains a key year to capitalize on opportunities and drive net sales growth. 

Galderma continues to reinforce its science-led innovation and medical education in dermatology. This includes advancing its R&D pipeline across product categories, while exploring external opportunities. It also includes generating new scientific data and insights to be presented at global congresses and company-led medical education events.

Based on a stronger-than-anticipated trajectory in the first half of the year, especially in Dermatological Skincare, Therapeutic Dermatology and Neuromodulators, Galderma is raising its net sales guidance for the full year. 

Net sales growth is now expected in the range of 19-21% at constant currency, up from previously 17-20%. Galderma is confirming its margin expansion expectation for the year, with a Core EBITDA margin of approximately 26% at constant currency, with the intent to continue investing behind growth opportunities in the second half.